Back to Search Start Over

Flavolignans from Silymarin as Nrf2 Bioactivators and Their Therapeutic Applications

Authors :
Nancy Vargas-Mendoza
Ángel Morales-González
Mauricio Morales-Martínez
Marvin A. Soriano-Ursúa
Luis Delgado-Olivares
Eli Mireya Sandoval-Gallegos
Eduardo Madrigal-Bujaidar
Isela Álvarez-González
Eduardo Madrigal-Santillán
José A. Morales-Gonzalez
Source :
Biomedicines, Vol 8, Iss 5, p 122 (2020)
Publication Year :
2020
Publisher :
MDPI AG, 2020.

Abstract

Silymarin (SM) is a mixture of flavolignans extracted from the seeds of species derived from Silybum marianum, commonly known as milk thistle or St. Mary’sthistle. These species have been widely used in the treatment of liver disorders in traditional medicine since ancient times. Several properties had been attributed to the major SM flavolignans components, identified as silybin, isosilybin, silychristin, isosilychristin, and silydianin. Previous research reported antioxidant and protective activities, which are probably related to the activation of the nuclear factor erythroid 2 (NFE2)-related factor 2 (Nrf2), known as a master regulator of the cytoprotector response. Nrf2 is a redox-sensitive nuclear transcription factor able to induce the downstream-associated genes. The disruption of Nrf2 signaling has been associated with different pathological conditions. Some identified phytochemicals from SM had shown to participate in the Nrf2 signaling pathway; in particular, they have been suggested as activators that disrupt interactions in the Keap1-Nrf2 system, but also as antioxidants or with additional actions regarding Nrf2 regulation. Thus, the study of these molecules makes them appear attractive as novel targets for the treatment or prevention of several diseases.

Details

Language :
English
ISSN :
22279059
Volume :
8
Issue :
5
Database :
Directory of Open Access Journals
Journal :
Biomedicines
Publication Type :
Academic Journal
Accession number :
edsdoj.604d56ed0cab4a90b216152f2378b05c
Document Type :
article
Full Text :
https://doi.org/10.3390/biomedicines8050122